Literature DB >> 11508667

Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C.

L E Adinolfi1, R Utili, A Andreana, M F Tripodi, M Marracino, M Gambardella, M Giordano, G Ruggiero.   

Abstract

The role of HCV RNA levels and host factors in the severity of liver injury was studied. Enrolled were 298 consecutive liver biopsy-proven chronic hepatitis (CH) C patients (179 men; median age: 52 years, range 19-68; CH, 198; cirrhosis, 100) and 18 chronic hepatitis C with normal ALT. HCV genotypes were: 1a, 4.3%; 1b, 53%; 2a/c, 28%; 3a, 7%; 4, 1.3%, and mixed 6.4%. Serum HCV RNA levels were similar for all genotypes (median: 2.8 x 10(6) eq/ml; range <0.2-69). In patients with chronic hepatitis without cirrhosis, the serum HCV RNA levels reflected the grade of liver necroinflammatory activity (R = 0.45; P < 0.001) and the stage of fibrosis (R = 0.51; P < 0.001), regardless of age, gender, HCV genotype, hepatic steatosis, and hepatic iron overload. Patients with high serum HCV RNA levels (> or =3 x 10(6) eq/ml) had higher ALT values (P < 0.002) than those with lower HCV RNA levels. Patients with normal ALT showed low HCV RNA levels (median: 0.82 x 10(6) eq/ml) and histological features of minimal or mild chronic hepatitis. Cirrhotic patients showed significantly lower levels of viremia than those with chronic hepatitis with a similar HAI. The data of a subgroup of 62 patients with an established time of infection showed that for a similar duration of disease, patients with serum HCV RNA levels > or =3 x 10(6) eq/ml had a significantly higher fibrosis score than those with lower levels. HAI and fibrosis score were significantly higher in patients with HCV RNA levels > or =3 x 10(6) eq/ml and grade 3-4 steatosis than those with lower HCV RNA levels and steatosis grades. The data indicate that the liver damage is correlated with the HCV RNA levels and that a high viral load acts together with steatosis in accelerating the progression of liver injury.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508667     DOI: 10.1023/a:1010697319589

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  30 in total

1.  Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients.

Authors:  L E Adinolfi; R Utili; G Ruggiero
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

2.  Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology.

Authors:  S Zeuzem; A Franke; J H Lee; G Herrmann; B Ruster; W K Roth
Journal:  Hepatology       Date:  1996-11       Impact factor: 17.425

3.  HCV viraemia and liver injury in symptom-free blood donors.

Authors:  N Yuki; N Hayashi; T Kamada
Journal:  Lancet       Date:  1993-08-14       Impact factor: 79.321

4.  Serum HCV RNA levels in chronic HCV hepatitis measured by quantitative PCR assay; correlation with serum AST.

Authors:  U Kumar; H C Thomas; J Monjardino
Journal:  J Virol Methods       Date:  1994-04       Impact factor: 2.014

5.  Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis.

Authors:  L Benvegnù; P Pontisso; D Cavalletto; F Noventa; L Chemello; A Alberti
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

6.  Correlation between the serum level of hepatitis C virus RNA and disease activities in acute and chronic hepatitis C.

Authors:  T Gunji; N Kato; S Mori; Y Ootsuyama; M Hijikata; M Imawari; K Shimotohno
Journal:  Int J Cancer       Date:  1992-11-11       Impact factor: 7.396

7.  Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

Authors:  J Y Lau; G L Davis; J Kniffen; K P Qian; M S Urdea; C S Chan; M Mizokami; P D Neuwald; J C Wilber
Journal:  Lancet       Date:  1993-06-12       Impact factor: 79.321

8.  Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease.

Authors:  N Kato; O Yokosuka; K Hosoda; Y Ito; M Ohto; M Omata
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

9.  Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients.

Authors:  S Pol; H Fontaine; F Carnot; H Zylberberg; P Berthelot; C Bréchot; B Nalpas
Journal:  J Hepatol       Date:  1998-07       Impact factor: 25.083

10.  Hepatitis C virus genotypes are not responsible for development of serious liver disease.

Authors:  M Yamada; S Kakumu; K Yoshioka; Y Higashi; K Tanaka; T Ishikawa; M Takayanagi
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

View more
  27 in total

1.  Hepatitis C update.

Authors:  Shimian Zou; Leslie Forrester; Antonio Giulivi
Journal:  Can J Public Health       Date:  2003 Mar-Apr

2.  Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia.

Authors:  S M Gadalla; L R Preiss; M E Eyster; J J Goedert
Journal:  J Viral Hepat       Date:  2011-03       Impact factor: 3.728

Review 3.  Analytical and biological variables influencing quantitative hepatitis C virus (HCV) measurement in HIV-HCV coinfection.

Authors:  C L Cooper; Curtis L Cooper; Paul MacPherson; William Cameron
Journal:  Can J Gastroenterol       Date:  2006-01       Impact factor: 3.522

4.  Response of combination therapy on viral load and disease severity in chronic hepatitis C.

Authors:  Deepak Kumar; Abdul Malik; Mohammad Asim; Anita Chakravarti; Rakha H Das; Premashis Kar
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

5.  Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi.

Authors:  Michele Merli; Carlo Visco; Michele Spina; Stefano Luminari; Virginia Valeria Ferretti; Manuel Gotti; Sara Rattotti; Valeria Fiaccadori; Chiara Rusconi; Clara Targhetta; Caterina Stelitano; Alessandro Levis; Achille Ambrosetti; Davide Rossi; Luigi Rigacci; Alfonso Maria D'Arco; Pellegrino Musto; Annalisa Chiappella; Luca Baldini; Maurizio Bonfichi; Luca Arcaini
Journal:  Haematologica       Date:  2013-11-22       Impact factor: 9.941

Review 6.  Genotype 3 Infection: The Last Stand of Hepatitis C Virus.

Authors:  Austin Chan; Keyur Patel; Susanna Naggie
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

7.  Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation.

Authors:  Ashly E Jordan; David C Perlman; Charles M Cleland; Katarzyna Wyka; Bruce R Schackman; Denis Nash
Journal:  J Clin Virol       Date:  2020-01-27       Impact factor: 3.168

8.  Steatosis is a lot more than holes in hepatocytes.

Authors:  Subrata Chakrabarti
Journal:  Saudi J Gastroenterol       Date:  2009-01       Impact factor: 2.485

Review 9.  Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Authors:  Amedeo Lonardo; Luigi Elio Adinolfi; Luciano Restivo; Stefano Ballestri; Dante Romagnoli; Enrica Baldelli; Fabio Nascimbeni; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

10.  Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients.

Authors:  Weiping Cai; Aiping Qin; Pengle Guo; Dehong Yan; Fengyu Hu; Qiong Yang; Min Xu; Yongshui Fu; Jie Zhou; Xiaoping Tang
Journal:  J Clin Immunol       Date:  2013-01-26       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.